CHELSEY WINDHAM: Open Payments
NPI 1477824902 · DIBERVILLE, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,498 in 76 payments from 18 companies in 2025. Trend: 2023 $276 · 2024 $1,257 · 2025 $1,498
Food & beverage: $1,498
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 10 | $258 |
| ABBVIE INC. | 15 | $232 |
| Amgen Inc. | 11 | $154 |
| Lilly USA, LLC | 8 | $132 |
| CVRx, Inc. | 1 | $124 |
| Axsome Therapeutics, Inc. | 5 | $119 |
| AstraZeneca Pharmaceuticals LP | 6 | $94 |
| GlaxoSmithKline, LLC. | 4 | $72 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $62 |
| Actelion Pharmaceuticals US, Inc. | 2 | $47 |
Products named: Ozempic, MOUNJARO, Barostim Neo System, EVENITY, Auvelity, QULIPTA, UBRELVY, CAPLYTA.
Industry payments across MS — which companies pay providers there.
